Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054431 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00054431: Completed Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by National Cancer Institute (NCI).
NCT00054431 is a Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 173-participant average among 11 other Accelerated Phase Chronic Myelogenous Leukemia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054431, a Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving imatinib mesylate together with decitabine may kill more cancer cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
- DRUG decitabine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00054431 record still lists
NCT00054431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 173-participant average among 11 other Accelerated Phase Chronic Myelogenous Leukemia trials with a reported enrollment target (54% lower).
The record links to 5 conditions, with Accelerated Phase Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00054431 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00054431 about?
NCT00054431 is a clinical study titled "Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia". This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs us...
What is the current status of trial NCT00054431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2003-01.
What conditions does trial NCT00054431 study?
This clinical trial studies the following conditions: Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00054431?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), decitabine (DRUG).
Who is sponsoring clinical trial NCT00054431?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054431 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Accelerated Phase Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00054431's enrollment target sits among peer trials
80 4th of 11 higher than 8 of 11 other Accelerated Phase Chronic Myelogenous Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Accelerated Phase Chronic Myelogenous Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
COMPLETED · Phase 2
-
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
ACTIVE NOT RECRUITING
-
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia